Cytomegalovirus hepatitis and ganciclovir treatment in immunocompetent children.
Neonatal cholestasis is a prolonged elevation of the serum levels of conjugated bilirubin beyond the first 14 days of life. Commonest etiologies include extrahepatic conditions like biliary atresia, intrahepatic like congenital malformations, infections and inborn errors of metabolism. TORCH infections constitute 22% cases of neonatal hepatitis, of which Cytomegalovirus is the commonest agent. Ganciclovir and its prodrug valganciclovir are recommended in the management of Cytomegalovirus infection. We, hereby report a 2 month old child, a case of Cytomegalovirus induced neonatal cholestasis with marked improvement in clinical and biochemical parameters, post treatment with intravenous ganciclovir.